Pharmigene, Inc. (TPEX:7595)
Taiwan · Delayed Price · Currency is TWD 12.35
+0.15 (1.23%)
Sep 25, 2025, 12:15 PM CST
Pharmigene Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| 149.25 | 116.53 | 132.71 | 133.8 | 129.35 | 101.35 | Upgrade | |
Revenue Growth (YoY) | 17.45% | -12.19% | -0.82% | 3.44% | 27.63% | 55.26% | Upgrade |
Cost of Revenue | 101.36 | 75.06 | 90.17 | 89.07 | 83.31 | 57.06 | Upgrade |
Gross Profit | 47.89 | 41.47 | 42.54 | 44.73 | 46.05 | 44.29 | Upgrade |
Selling, General & Admin | 79.01 | 93.13 | 71.32 | 58.9 | 54.73 | 48.03 | Upgrade |
Research & Development | 36.7 | 29.63 | 30.34 | 29.69 | 15.49 | 8.72 | Upgrade |
Operating Expenses | 115.49 | 126.7 | 101.73 | 89.18 | 68.78 | 58.16 | Upgrade |
Operating Income | -67.6 | -85.23 | -59.19 | -44.45 | -22.74 | -13.87 | Upgrade |
Interest Expense | -13.25 | -12.1 | -7.91 | -0.2 | -0.31 | -0.36 | Upgrade |
Interest & Investment Income | 1.02 | 1.07 | 1.69 | 1.5 | 0.68 | 3.53 | Upgrade |
Earnings From Equity Investments | -0.88 | -4.51 | -4.6 | -0.72 | -1.44 | - | Upgrade |
Currency Exchange Gain (Loss) | -1.44 | -0.05 | -0.23 | -0.22 | -0.39 | 0.21 | Upgrade |
Other Non Operating Income (Expenses) | 3.9 | 3.54 | 0.17 | 0.75 | 0.42 | 0.17 | Upgrade |
EBT Excluding Unusual Items | -78.25 | -97.29 | -70.07 | -43.35 | -23.77 | -10.32 | Upgrade |
Gain (Loss) on Sale of Investments | 6.62 | 14.46 | -0.51 | 0.21 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 0.4 | - | 0.83 | Upgrade |
Asset Writedown | -3.53 | - | -2.05 | - | - | - | Upgrade |
Other Unusual Items | -0.33 | - | - | 0.03 | - | - | Upgrade |
Pretax Income | -75.48 | -82.83 | -72.63 | -42.71 | -23.77 | -9.5 | Upgrade |
Income Tax Expense | 0.03 | 0.04 | 0.02 | 0.01 | -0.34 | 1.71 | Upgrade |
Net Income | -75.51 | -82.86 | -72.65 | -42.72 | -23.43 | -11.21 | Upgrade |
Net Income to Common | -75.51 | -82.86 | -72.65 | -42.72 | -23.43 | -11.21 | Upgrade |
Shares Outstanding (Basic) | 50 | 50 | 45 | 43 | 43 | 34 | Upgrade |
Shares Outstanding (Diluted) | 50 | 50 | 45 | 43 | 43 | 34 | Upgrade |
Shares Change (YoY) | 3.03% | 10.96% | 4.63% | - | 28.48% | 53.99% | Upgrade |
EPS (Basic) | -1.50 | -1.64 | -1.60 | -0.98 | -0.54 | -0.33 | Upgrade |
EPS (Diluted) | -1.50 | -1.64 | -1.60 | -0.98 | -0.54 | -0.33 | Upgrade |
Free Cash Flow | -84.5 | -109.42 | -742.85 | -33.96 | -31.98 | -21.63 | Upgrade |
Free Cash Flow Per Share | -1.67 | -2.17 | -16.33 | -0.78 | -0.74 | -0.64 | Upgrade |
Gross Margin | 32.09% | 35.59% | 32.06% | 33.43% | 35.60% | 43.70% | Upgrade |
Operating Margin | -45.29% | -73.13% | -44.60% | -33.22% | -17.58% | -13.69% | Upgrade |
Profit Margin | -50.59% | -71.11% | -54.74% | -31.92% | -18.12% | -11.06% | Upgrade |
Free Cash Flow Margin | -56.62% | -93.90% | -559.76% | -25.38% | -24.72% | -21.34% | Upgrade |
EBITDA | -46.2 | -65.21 | -43.19 | -31.67 | -14.63 | -8.74 | Upgrade |
EBITDA Margin | -30.96% | -55.96% | -32.55% | -23.67% | -11.31% | -8.62% | Upgrade |
D&A For EBITDA | 21.39 | 20.01 | 15.99 | 12.78 | 8.1 | 5.14 | Upgrade |
EBIT | -67.6 | -85.23 | -59.19 | -44.45 | -22.74 | -13.87 | Upgrade |
EBIT Margin | -45.29% | -73.13% | -44.60% | -33.22% | -17.58% | -13.69% | Upgrade |
Advertising Expenses | - | - | - | - | - | 2.65 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.